ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

posted on May 16, 2018 11:35AM

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

They used the pan-BET inhibitors JQ1 (not in clinical trials) and iBET762 (in clinical trials as GSK525762). Zenith was already planning a ZEN-3694 + PARP inhibitor trial (outlined in BIO Europe March 2018 timeline slide) in Homologous recombination deficiency (HRD) patients with ovarian, prostate or breast cancer. Perhaps this recent finding gives them another subset of ovarian cancers to focus on too. Thanks to Aureus over on IV for posting. However, not sure if RVX-208/apabetalone would work for this since it is a bromodomain-2 selective compound, not a pan-BET inhibitor like JQ1, iBET762 and ZEN-3694.